Heartflow (NASDAQ:HTFL) Hits New 12-Month Low After Insider Selling

Key Points

• Heartflow shares hit a new 52-week low (trading as low as $25.36, last $26.42) after heavy insider selling, including CEO John C.M. Farquhar selling 22,562 shares (~$619,553) and major shareholder Bain Capital Life Sciences selling 2,000,000 shares for about $56.1 million.
• Despite the insider exits and a 3.3% intraday drop, analysts remain largely positive (five Buys, two Holds, one Sell) with a consensus "Moderate Buy" and an average target of $38.50, while the stock trades below its 50‑day moving average ($30.26) and has a market cap of ~$2.25 billion.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) shares hit a new 52-week low on Wednesday after an insider sold shares in the company. The stock traded as low as $25.36 and last traded at $26.42, with a volume of 575570 shares changing hands. The stock had previously closed at $27.30.

Specifically, CEO John C.M. Farquhar sold 22,562 shares of the business's stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52. Following the completion of the transaction, the chief executive officer directly owned 591,656 shares in the company, valued at approximately $16,246,873.76. The trade was a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 8,000 shares of the business's stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total transaction of $218,560.00. Following the transaction, the director owned 36,413 shares of the company's stock, valued at approximately $994,803.16. This represents a 18.01% decrease in their position. The SEC filing for this sale provides additional information. In other news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the transaction, the insider directly owned 10,448,158 shares of the company's stock, valued at $293,070,831.90. This trade represents a 16.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Analyst Ratings Changes

Several research analysts have weighed in on HTFL shares. Weiss Ratings reiterated a "sell (d)" rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company initiated coverage on Heartflow in a report on Wednesday, January 28th. They set an "overweight" rating and a $38.00 price objective on the stock. Stifel Nicolaus increased their target price on Heartflow from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Canaccord Genuity Group lifted their price target on shares of Heartflow from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Heartflow from $36.00 to $40.00 and gave the stock an "overweight" rating in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $38.50.

Heartflow Trading Down 3.3%

The stock has a fifty day moving average price of $30.26. The company has a market cap of $2.25 billion and a price-to-earnings ratio of -14.58.

Institutional Investors Weigh In On Heartflow

Several hedge funds have recently bought and sold shares of HTFL. TFC Financial Management Inc. acquired a new stake in shares of Heartflow in the third quarter valued at approximately $40,000. Legal & General Group Plc bought a new position in Heartflow during the third quarter worth $59,000. Strs Ohio acquired a new position in Heartflow in the 4th quarter valued at about $99,000. Y Intercept Hong Kong Ltd bought a new position in Heartflow in the 3rd quarter valued at about $234,000. Finally, Staley Capital Advisers Inc. acquired a new stake in Heartflow during the fourth quarter worth approximately $204,000.

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.